<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327755</url>
  </required_header>
  <id_info>
    <org_study_id>RCT-32122010</org_study_id>
    <nct_id>NCT01327755</nct_id>
  </id_info>
  <brief_title>Rwanda Selenium Supplementation Clinical Trial</brief_title>
  <acronym>RSST</acronym>
  <official_title>Effect of Selenium Supplementation on CD4 + Cell Recovery, Viral Suppression, Morbidity and Quality of Life of HIV Infected Patients in Rwanda: a Prospective, Double-Blinded, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Canadian College of Naturopathic Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Benefit Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wilfrid Laurier University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kibagabaga District Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinyinya Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Canadian College of Naturopathic Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis: The addition of selenium supplementation to cotrimoxazole will improve CD4
      counts, decrease opportunistic infections, decrease viral loads and delay the need for
      initiating antiretroviral therapy(ART) in Rwandan adult patients infected with HIV/ AIDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited from two health facilities (Kibagabaga District Hospital, and
      Kinyinya Health Center in Kigali), Rwanda that offer care and treatment for HIV/AIDS
      patients. Patients will be recruited during a 3-4 month period. Consenting adults who fit the
      inclusion criteria will be enrolled and followed for 2 years. Study assessments will occur at
      enrollment, 6, 12, 18, and 24 months after initiation of selenium supplementation.

      Participants will be randomized using a simple randomized block design to receive either
      cotrimoxazole and selenium or cotrimoxazole and an identically appearing placebo taken once
      daily for 2 years. Participants who do not return to the clinic as scheduled will be followed
      up at home.

      All consenting patients with CD4 count between 400 and 650 mm3 will be selected because they
      are at similar immunological level and hence they will not be eligible to start ARV treatment
      at the study start. The study will look at the efficacy of selenium supplementation to this
      already compromised group of patients at a similar stage of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 count</measure>
    <time_frame>Baseline, 6, 12, 18, and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>viral load</measure>
    <time_frame>Baseline, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of opportunistic infections</measure>
    <time_frame>Baseline, 6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antiretroviral therapy (ART)initiation</measure>
    <time_frame>Baseline, 6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>Selenium yeast containing selenomethionine 200 mcg per day for 2 years</description>
    <arm_group_label>Selenium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same number of pills, frequency, and duration as selenium intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; or = 21 years at enrollment

          -  Confirmed HIV positive with a CD4 range between 400 and 650 mm3

          -  HIV+ patients willing to participate in the study and who provide informed consent

          -  Pre-antiretroviral therapy (Pre-ART) at enrollment in study (not yet initiated ART)

          -  Willing to practice barrier method of birth control at all times

        Exclusion Criteria:

          -  Patients intending to be transferred out of the clinic catchment area before study
             ends

          -  Patients scheduled to start ART

          -  Moribund patients

          -  Pregnant women

          -  Unable or not wanting to commit to barrier method of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julius K Kamwesiga, MD MPH(cand)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rwanda Selenium Supplementation Clinical Trial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Don Warren, BSc ND DHANP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Benefit Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kibagabaga Hospital</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinyinya Health Center</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Rwanda</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selenium</keyword>
  <keyword>HIV/ AIDS</keyword>
  <keyword>CD4 counts</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

